News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Dendreon Corporation (DNDN) Slashes 15 Percent Of Jobs As Provenge Sales Disappoint


11/12/2013 7:25:59 AM

Dendreon is cutting staff but others are hiring! Check it out! (Isn't it tempting?)

Biotechnology company Dendreon Corp said it would restructure to cut costs after reporting another quarter of weak sales of its prostate cancer vaccine, Provenge. Net product revenue, reflecting Provenge sales, fell 13 percent to $68 million in the third quarter, short of analysts' average estimate of $76.3 million, according to Thomson Reuters I/B/E/S. Dendreon is watched closely due to the immense potential of cancer vaccines, but Provenge sales have never really taken off due to limited manufacturing capacity and uncertainty over reimbursements.

Don't forget, hundreds of biopharma companies are hiring! (We know you can't resist.)


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES